RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells could outsmart relapsed myeloma
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T c…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
Disease control Not yet recruitingThis early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough myeloma: Two-Drug combo takes on relapsed cancer
Disease control Not yet recruitingThis phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC